The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis-Reference-Cited by-同舟云学术

The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis

Published:2020-09 Issue:3 Volume:83 Page:839-846
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Simpson Eric,Bissonnette Robert,Eichenfield Lawrence F.,Guttman-Yassky Emma,King Brett,Silverberg Jonathan I.,Beck Lisa A.,Bieber Thomas,Reich Kristian,Kabashima Kenji,Seyger Marieke,Siegfried Elaine,Stingl Georg,Feldman Steven R.,Menter Alan,van de Kerkhof Peter,Yosipovitch Gil,Paul Carle,Martel Philippe,Dubost-Brama Ariane,Armstrong John,Chavda Rajeev,Frey Steve,Joubert Yolandi,Milutinovic Marina,Parneix Anne,Teixeira Henrique D.,Lin Chen-Yen,Sun Luna,Klekotka Paul,Nickoloff Brian,Dutronc Yves,Mallbris Lotus,Janes Jonathan M.,DeLozier Amy M.,Nunes Fabio P.,Paller Amy S.

Funder

Eli Lilly and Company

LEO Pharma

Pfizer

Regeneron

Galderma

Merck & Co

AbbVie

Incyte

Almirall

Amgen

AnaptysBio

Asana Biosciences

Boehringer Ingelheim

Celgene

Dermavant

DS Biopharma

Glenmark

Innovaderm

Janssen

Kiniksa

Kyowa Kirin

Leo Pharma

Novan

Ralexar

Sienna Biopharma

UCB

Union Therapeutics

Affibody

Avillion

Biogen

Bristol-Myers Squibb

Centocor

Covagen

Forward Pharma

Fresenius Medical Care

Galapagos

GlaxoSmithKline

Janssen-Cilag

Medac

Merck Sharp & Dohme

Novartis

Miltenyi Biotec

Ocean Pharma

Samsung Bioepis

Sanofi

Sun Pharma

Takeda

Valeant

Xenoport

Japan Tobacco

Maruho

Mitsubishi Tanabe

Ono

P&G

Taiho

Ortho Dermatology

Bellus

Menlo

Leo

Trevi

Pierre Fabre

Castle Creek

Publisher

Elsevier BV

Subject

Dermatology

Reference12 articles.

1. Atopic dermatitis;Bieber;N Engl J Med,2008

2. Therapeutic pipeline for atopic dermatitis: end of the drought?;Paller;J Allergy Clin Immunol,2017

3. What are the best outcome measurements for atopic eczema? a systematic review;Schmitt;J Allergy Clin Immunol,2007

4. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation;Schmitt;J Allergy Clin Immunol,2013

5. The Eczema Area and Severity Index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group;Hanifin;Exp Dermatol,2001

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lebrikizumab Combined with Topical Corticosteroids Improves Patient-reported Outcomes in Japanese Patients with Moderate-to-severe Atopic Dermatitis;Acta Dermato-Venereologica;2024-09-09

2. Consideration of treatment goals and termination algorithm for adolescent atopic dermatitis using upadacitinib;Journal of Cutaneous Immunology and Allergy;2024-08-22

3. Consensus Recommendations for the Management of Atopic Dermatitis in the United Arab Emirates;Dermatology and Therapy;2024-08-22

4. IL-22 in Atopic Dermatitis;Cells;2024-08-22

5. The Eczema Area and Severity Index: An update of progress and challenges in its measurement of atopic dermatitis after 20 years of use;Journal of the European Academy of Dermatology and Venereology;2024-08-19